Stammdaten
Daxor Corporation, a medical device company, provides blood volume measurement technology focused on blood volume testing. The company develops and markets BVA-100 Blood Volume Analyzer, a diagnostic blood test to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms for used in a broad range of medical and surgical conditions. The company was formerly known as Idant Corporation and changed its name to Daxor Corporation in May 1973. Daxor Corporation was incorporated in 1971 and is headquartered in Oak Ridge, Tennessee.
Unternehmen & Branche
| Name | DAXOR CORP |
|---|---|
| Ticker | DXR |
| CIK | 0000027367 |
| Boerse | US |
| Sektor | Healthcare |
| Industrie | Medical - Instruments & Supplies |
Wertpapier & Kennzahlen
| CUSIP | 239467103 |
|---|---|
| ISIN | US2394671034 |
| Typ | Common Stock |
| Marktkapitalisierung | 50,3 Mio. USD |
| Beta | 0,14 |
| Dividendenrendite | 0,00 % |
Externe Quellen: SEC EDGAR » · FMP-Profil » · Yahoo Finance »
Finanzkennzahlen (SEC XBRL)
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2011-12-31 | 10-K | 1,446,345 | -7,185,639 | 85,724,861 | 36,216,591 |
Fondsaktivität (Vorquartalsvergleich)
| Fonds | Aktuell (Stk) | Vorquartal (Stk) | Veränderung (Stk) | Wert (USD) | Status | Δ | Trend |
|---|---|---|---|---|---|---|---|
| VANGUARD GROUP INC | 49,028 | 0 | 49,028 | 723,163 | Neu | +100,0% | |
| RENAISSANCE TECHNOLOGIES LLC | 28,221 | 0 | 28,221 | 416,260 | Neu | +100,0% | |
| Empirical Financial Services, LLC d.b.a. Empirical Wealth Management | 25,192 | 0 | 25,192 | 244,867 | Neu | +100,0% | |
| MORGAN STANLEY | 3,237 | 0 | 3,237 | 47,746 | Neu | +100,0% | |
| SBI Securities Co., Ltd. | 3,128 | 0 | 3,128 | 46,138 | Neu | +100,0% | |
| OSAIC HOLDINGS, INC. | 500 | 0 | 500 | 7,375 | Neu | +100,0% | |
| UBS Group AG | 90 | 0 | 90 | 1,328 | Neu | +100,0% | |
| JPMORGAN CHASE & CO | 5 | 0 | 5 | 74 | Neu | +100,0% | |
| WELLS FARGO & COMPANY/MN | 0 | 0 | 0 | 2 | Neu | +100,0% |
Insider-Transaktionen (12 Monate)
| Datum | Insider | Rolle | Typ | Stückzahl | Kurs | Wert (USD) | Δ | Trend |
|---|---|---|---|---|---|---|---|---|
| 2026-04-08 | Feldschuh Michael Richard | Director, Officer, Chief Executive Officer | Open Market Purchase | 1,000 | 9.07 | 9,070.00 | +20,4% | |
| 2026-03-31 | Michel Robert J | Officer, Chief Financial Officer | Open Market Purchase | 1,000 | 9.90 | 9,900.00 | +22,2% | |
| 2026-03-20 | Jefferies John | Officer, Chief Medical Officer | Open Market Purchase | 2,285 | 0.00 | 0.00 | 0,0% | |
| 2026-03-20 | Jefferies John | Officer, Chief Medical Officer | Open Market Purchase | 3,656 | 0.00 | 0.00 | 0,0% | |
| 2025-12-09 | Michel Robert J | Officer, Chief Financial Officer | Open Market Purchase | 3,000 | 12.50 | 37,500.00 | +84,3% | |
| 2025-12-09 | Feldschuh Jonathan Adam | Director, Officer, Chief Scientific Officer | Open Market Purchase | 18,000 | 12.50 | 225,000.00 | +505,7% | |
| 2025-11-12 | Jefferies John | Officer, Chief Medical Officer | Open Market Purchase | 2,344 | 12.80 | 30,003.20 | +67,4% |
Fail-to-Deliver (6 Monate)
| Datum | FTD-Menge | Kurs | Wert (USD) |
|---|---|---|---|
| 2026-04-02 | 271 | 10,03 | 2.718 |
| 2026-03-25 | 403 | 10,23 | 4.123 |
| 2026-03-24 | 811 | 10,51 | 8.524 |
| 2026-03-23 | 7 | 10,94 | 77 |
| 2026-03-09 | 53 | 11,35 | 602 |
| 2026-03-06 | 2 | 11,59 | 23 |
| 2026-02-17 | 324 | 12,61 | 4.086 |
Top-Fondshalter
Stand: 31.03.2026
| Fonds | Anteile | Wert (USD) | Anteil (%) |
|---|---|---|---|
| Empirical Financial Services, LLC d.b.a. Empirical Wealth Management | 25,192 | 244,867 | 100.00 |